
    
      This is a phase 2a, randomized, double-blind, placebo-controlled, multi-dose, 2-way
      cross-over study designed to examine the effect of IPI-145 on lung function and inflammatory
      indices in mild, allergen-reactive asthmatic subjects undergoing allergen challenge.
    
  